drugset / Trial / NCT02586233
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
RandomizedSingle-groupDouble-blindTreatment
Summary
This is a Phase 1b/2, double-blind (study participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040b in participants with Acute Ischemic Stroke (AIS).
Timeline
- Start
- 2015-09
- Primary completion
- 2019-08-13
- Completion
- 2019-08-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DS-1040b | Small molecule | 0.6 mg | Intravenous |
| Subject | DS-1040b | Small molecule | 9.6 mg | Intravenous |